Biote Corp. reports developments tied to its hormone optimization and healthy aging business, which supports Biote-certified medical providers through training, practice development, operational services and personalized hormone therapy programs. Company updates commonly cover procedure revenue, dietary supplement sales, new provider and clinic growth, commercial team expansion and technology or sales investments aimed at the practitioner network.
Biote news also includes quarterly financial results, outlook commentary, share repurchases, organizational changes and product-supply matters. Its operating updates distinguish procedure-based revenue from Biote-branded dietary supplements and have included disclosures related to Asteria Health, the company’s wholly owned 503B manufacturing subsidiary.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
biote Corp. (Nasdaq: BTMD) announced that it will release its first quarter financial results on May 9, 2023, after market close. A conference call to discuss these results is set for May 10, 2023, at 8:30 a.m. ET. Investors can access the call via phone or a live webcast. Biote specializes in personalized hormone optimization therapies aimed at transforming healthy aging. The company operates within an $8 billion global market, focusing on training practitioners to address hormone-related aging conditions. The press release also includes forward-looking statements highlighting various risks, such as regulatory pressures and competition. Investors are encouraged to review Biote's Annual Report and other SEC filings for further details on risks and uncertainties.
Biote (NASDAQ: BTMD) announced the appointment of John Denne as General Manager of its Men’s Health Division, a move aimed at expanding the company's footprint in the male hormone replacement therapy market. Denne brings over 30 years of healthcare experience, having previously driven commercial success at Endo International in Men’s Health. Terry Weber, CEO of Biote, expressed excitement over Denne’s track record in brand recognition and sustainable growth. Denne echoed these sentiments, highlighting the significant opportunity in hormone replacement therapy for men, which remains largely unmet. Biote operates in a $7 billion global market focused on hormone optimization therapies, and this leadership change is anticipated to accelerate their growth initiatives.
Biote (NASDAQ: BTMD) announced strong financial results for Q4 and the full year 2022, achieving record revenue of $165.0 million and a 24.6% increase in Adjusted EBITDA to $50.1 million. The Q4 revenue rose 18.5% to $44.5 million, supported by a 40% increase in Adjusted EBITDA to $13.1 million. Despite a net income of $1.3 million, the company reported an operating loss of $60.7 million due to substantial stock compensation and transaction-related expenses. For 2023, Biote anticipates revenue between $190-$200 million and Adjusted EBITDA of $56-$60 million, reflecting a continued focus on growth and market expansion.